We thank Waitzman et al1 for their comments. We agree that MRAs raise hyperkalemia risk and should be used cautiously to avoid subsequent higher rates of hyperkalemia.2 While there is evidence that nonsteroidal MRAs including finerenone increase potassium to a lesser extent than spironolactone,3 clinicians will need to exercise caution when using these therapies in patients with CKD.